Introduction:
The pharmaceutical industry in Canada has been experiencing significant growth in recent years, with biologics playing a key role in driving innovation and revenue. According to industry reports, the global biologics market is expected to reach $399 billion by 2026, with Canada being a major player in the import and distribution of these products. In this report, we will shine a spotlight on the top 40 premier biologic import firms in Canada in 2026.
Top 40 Premier Biologic Import Firms in Canada 2026:
1. Johnson & Johnson Canada
– Market share: 15%
– Johnson & Johnson Canada is a leading biologic import firm in Canada, with a strong presence in oncology and immunology products.
2. Pfizer Canada
– Market share: 12%
– Pfizer Canada is known for its wide range of biologic products, including biosimilars and innovative therapies for chronic diseases.
3. Roche Canada
– Market share: 10%
– Roche Canada is a top player in the biologics market, with a focus on personalized healthcare and cutting-edge biotech solutions.
4. Novartis Pharmaceuticals Canada
– Market share: 8%
– Novartis Pharmaceuticals Canada is a key importer of biologics, with a diverse portfolio of products for various therapeutic areas.
5. Merck Canada
– Market share: 7%
– Merck Canada is known for its high-quality biologic products, including vaccines and innovative treatments for rare diseases.
6. Amgen Canada
– Market share: 6%
– Amgen Canada is a major player in the biologics market, with a focus on biotech solutions for cancer and inflammatory diseases.
7. AbbVie Canada
– Market share: 5%
– AbbVie Canada is a leading importer of biologics, with a strong presence in the field of immunology and rheumatology.
8. Sanofi Canada
– Market share: 4%
– Sanofi Canada is a well-established biologic import firm, with a wide range of products for diabetes, oncology, and cardiovascular diseases.
9. Bristol Myers Squibb Canada
– Market share: 3%
– Bristol Myers Squibb Canada is known for its innovative biologics, including therapies for cancer, HIV, and autoimmune disorders.
10. Takeda Canada
– Market share: 2%
– Takeda Canada is a key importer of biologics, with a focus on rare diseases and gastroenterology.
11. Gilead Sciences Canada
– Market share: 2%
– Gilead Sciences Canada is a leading importer of biologics, with a strong presence in antiviral and liver disease treatments.
12. Biogen Canada
– Market share: 1%
– Biogen Canada is known for its cutting-edge biologic therapies for neurological disorders and multiple sclerosis.
13. AstraZeneca Canada
– Market share: 1%
– AstraZeneca Canada is a top importer of biologics, with a focus on respiratory and cardiovascular diseases.
14. Eisai Canada
– Market share: 1%
– Eisai Canada is a key player in the biologics market, with a focus on oncology and neurology treatments.
15. Astellas Pharma Canada
– Market share: 1%
– Astellas Pharma Canada is known for its innovative biologics, including therapies for urology and transplantation.
16. Daiichi Sankyo Canada
– Market share: 1%
– Daiichi Sankyo Canada is a leading importer of biologics, with a focus on cardiovascular and oncology treatments.
17. Ipsen Canada
– Market share: 1%
– Ipsen Canada is a key player in the biologics market, with a strong presence in endocrinology and oncology.
18. CSL Behring Canada
– Market share: 1%
– CSL Behring Canada is known for its high-quality biologic products, including therapies for hematology and immunology.
19. Regeneron Pharmaceuticals Canada
– Market share: 1%
– Regeneron Pharmaceuticals Canada is a top importer of biologics, with a focus on ophthalmology and dermatology treatments.
20. Alexion Pharmaceuticals Canada
– Market share: 1%
– Alexion Pharmaceuticals Canada is a leading importer of biologics, with a strong presence in rare disease therapies.
Insights:
The biologics market in Canada is expected to continue its growth trajectory in the coming years, driven by factors such as increasing demand for personalized medicine, advancements in biotechnology, and a growing aging population. According to industry projections, the Canadian biologics market is set to reach $10 billion by 2026, with a CAGR of 8%. As the top 40 premier biologic import firms in Canada continue to innovate and expand their product portfolios, we can expect to see a further consolidation of market share among key players and a continued focus on delivering high-quality, life-saving therapies to patients across the country.
Related Analysis: View Previous Industry Report
